Prakt. lékáren. 2018; 14(2): 56-62 [Interní Med. 2018; 20(2): 74-80]

Modern aspects of allergic rhinitis

Irena Krčmová, Jakub Novosad
Ústav klinické imunologie a alergologie, Fakultní nemocnice Hradec Králové

Allergic diseases are seen as systemic diseases with organ symptoms. Allergic rhinitis is defined as a group of nasal symptoms,arising from an underlying IgE-mediated inflammation following exposure of the nasal mucosa to allergens. The basic feature ofallergic rhinitis is a persistent eosinophilic inflammation accompanied by typical clinical manifestations. Allergic rhinitis developson the basis of numerous environmental factors in a genetically predisposed individual. The symptoms of rhinitis may be spontaneouslyreversible or resolve following treatment. The management of allergic rhinitis involves patient education, eliminationof allergens, pharmacotherapy, and specific allergen immunotherapy. Sublingual tablet dosage form of allergen immunotherapy(grass pollens, house dust mites) is a modern alternative to subcutaneous treatment. This treatment reduces the severity ofallergy symptoms, lowers the risk of developing new allergic sensitizations, and prevents the development of clinical asthma inpatients treated for allergic rhinitis.

Keywords: allergic rhinitis, pharmacotherapy, allergen immunotherapy

Published: June 20, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krčmová I, Novosad J. Modern aspects of allergic rhinitis. Praktické lékárenství. 2018;14(2):56-62.
Download citation

References

  1. A?t-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy. 2009 Jan. 64 (1): 123-148. Go to original source... Go to PubMed...
  2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and itsImpact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008: 63(Suppl 86): 8-160. Go to original source... Go to PubMed...
  3. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group., World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001 Nov. 108 (5 Suppl): S147-334. Go to original source... Go to PubMed...
  4. Cauwenberge P, et al: Consensus statement on the treatment of allergic rhinitis. EuropeanAcademy of Allergology and ClinicalImmunology, Allergy; 2000; 55 (2): 116-134. Go to original source... Go to PubMed...
  5. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol. 1998 May. 101(5): 633-637. Go to original source... Go to PubMed...
  6. Global initiative for asthma. http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/
  7. Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017 Nov 2.
  8. Petrů V, Chrobok V, Klozar J. Alergická rýma: Zásady diagnostiky a léčby Mediforum, 2. přepracované vydání, 2010, nakladatelství Maxdorf, s. r. o.
  9. Nayak AS. The asthma and allergic rhinitis link. Allergy Asthma Proc. 2003 Nov-Dec. 24(6): 395-402. Go to PubMed...
  10. Gendo K, Larson EB. Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis. Ann Intern Med. 2004 Feb 17. 140(4): 278-289. Go to original source... Go to PubMed...
  11. Krčmová I, Malá E. Užití solných roztoků v souběžné léčbě alergické rýmy, Alergie 2011; 1: 66-73.
  12. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: AAAAI/EAACI/PRACTAL consensus report. J Allergy Clin Immunol 2013; 131: 1288-1296. Go to original source... Go to PubMed...
  13. Rybníček O, Seberová E, et al. Průvodce specifickou alergenovou imunoterapií (SIT), Doporučení ČSAKI 2009, edit. ČIPA, o. p. s., vyd. Tigis.
  14. Wahn U, Klimek L, Ploszczuk A, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2012; 130: 886-893. Go to original source... Go to PubMed...
  15. Špičák V, Petrů V. Století specifické alergenové imunoterapie 1911-2011. Alergie 2011; 13(Supl. 1): 1-7.
  16. Petrů V. Novinky v alergenové imunoterapii. Interní medicína pro praxi. 2017; 19(2): 78-81. Go to original source...
  17. Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol 2014; 134(1): 75-81. Go to original source... Go to PubMed...
  18. Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016; 137(2): 444-451. Go to original source... Go to PubMed...
  19. Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015; 35(6): 1494-1501. Go to original source... Go to PubMed...
  20. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014; 134: 568-575. Go to original source... Go to PubMed...
  21. Virchow JC, Becker V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma. A randomized clinical trial. JAMA, 2016; 315(16): 1715-1725. Go to original source... Go to PubMed...
  22. Didier A, Wahn U, Horak F, et al. Five grass pollen sublingual immunotherapy tablet for the treatment of grass-pollen induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol 2014; 10: 1309-1324. Go to original source... Go to PubMed...
  23. Dahl R, Roberts G, de Blic J, et al. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconiunctivitis. Allergy Asthma Proc 2016; 37: 92-104. Go to original source... Go to PubMed...
  24. Valovirta E, Cronjäger R, Peterssen TH, et al. Top-line results from the five-years landmark Grazax asthma prevention (GAP) trial in children. Allergy 2016; 71(suppl 102): 98-99.
  25. EAACI AIT guidelines II, dostupné na www.eaaci.org




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.